MX2012013945A - Nuevas formas de rifaximina y usos de las mismas. - Google Patents
Nuevas formas de rifaximina y usos de las mismas.Info
- Publication number
- MX2012013945A MX2012013945A MX2012013945A MX2012013945A MX2012013945A MX 2012013945 A MX2012013945 A MX 2012013945A MX 2012013945 A MX2012013945 A MX 2012013945A MX 2012013945 A MX2012013945 A MX 2012013945A MX 2012013945 A MX2012013945 A MX 2012013945A
- Authority
- MX
- Mexico
- Prior art keywords
- new forms
- rifaximine
- same
- rifaximin
- cocristal
- Prior art date
Links
- NZCRJKRKKOLAOJ-XRCRFVBUSA-N rifaximin Chemical compound OC1=C(C(O)=C2C)C3=C4N=C5C=C(C)C=CN5C4=C1NC(=O)\C(C)=C/C=C/[C@H](C)[C@H](O)[C@@H](C)[C@@H](O)[C@@H](C)[C@H](OC(C)=O)[C@H](C)[C@@H](OC)\C=C\O[C@@]1(C)OC2=C3C1=O NZCRJKRKKOLAOJ-XRCRFVBUSA-N 0.000 title abstract 4
- 229960003040 rifaximin Drugs 0.000 title abstract 4
- GLUUGHFHXGJENI-UHFFFAOYSA-N Piperazine Chemical compound C1CNCCN1 GLUUGHFHXGJENI-UHFFFAOYSA-N 0.000 abstract 4
- 238000000034 method Methods 0.000 abstract 1
- 238000002360 preparation method Methods 0.000 abstract 1
- 238000002560 therapeutic procedure Methods 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D498/22—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains four or more hetero rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
- A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/12—Antidiarrhoeals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
- C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
- C07D491/04—Ortho-condensed systems
- C07D491/044—Ortho-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring
- C07D491/048—Ortho-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring the oxygen-containing ring being five-membered
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Epidemiology (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Oncology (AREA)
- Communicable Diseases (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
Applications Claiming Priority (7)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US35128110P | 2010-06-03 | 2010-06-03 | |
| US35750510P | 2010-06-22 | 2010-06-22 | |
| US36324110P | 2010-07-10 | 2010-07-10 | |
| US36351110P | 2010-07-12 | 2010-07-12 | |
| US36718510P | 2010-07-23 | 2010-07-23 | |
| US41659310P | 2010-11-23 | 2010-11-23 | |
| PCT/US2011/039085 WO2011153444A1 (en) | 2010-06-03 | 2011-06-03 | New forms of rifaximin and uses thereof |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MX2012013945A true MX2012013945A (es) | 2013-05-06 |
Family
ID=45067089
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2012013945A MX2012013945A (es) | 2010-06-03 | 2011-06-03 | Nuevas formas de rifaximina y usos de las mismas. |
Country Status (18)
| Country | Link |
|---|---|
| US (2) | US8513275B2 (enExample) |
| EP (1) | EP2575464A4 (enExample) |
| JP (1) | JP2013527246A (enExample) |
| KR (1) | KR20130086338A (enExample) |
| CN (1) | CN103269587A (enExample) |
| AU (1) | AU2011261283B2 (enExample) |
| BR (1) | BR112012030783A2 (enExample) |
| CA (1) | CA2800668A1 (enExample) |
| CR (1) | CR20120620A (enExample) |
| EA (1) | EA022490B1 (enExample) |
| IL (1) | IL222900A (enExample) |
| MX (1) | MX2012013945A (enExample) |
| NZ (2) | NZ710780A (enExample) |
| PH (1) | PH12012502393A1 (enExample) |
| SG (2) | SG10201507035UA (enExample) |
| TN (1) | TN2012000533A1 (enExample) |
| WO (1) | WO2011153444A1 (enExample) |
| ZA (1) | ZA201208770B (enExample) |
Families Citing this family (21)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| PT1698630E (pt) | 2005-03-03 | 2014-09-15 | Alfa Wassermann Spa | Novas formas polimorfas de rifaximina, processos para a sua produção e a sua utilização nas preparações medicinais |
| US8486956B2 (en) | 2008-02-25 | 2013-07-16 | Salix Pharmaceuticals, Ltd | Forms of rifaximin and uses thereof |
| GEP20135898B (en) | 2008-02-25 | 2013-08-12 | Salix Pharmaceuticals Ltd | Rifaximin forms and usage |
| US9018684B2 (en) | 2009-11-23 | 2015-04-28 | California Institute Of Technology | Chemical sensing and/or measuring devices and methods |
| IT1398550B1 (it) | 2010-03-05 | 2013-03-01 | Alfa Wassermann Spa | Formulazioni comprendenti rifaximina utili per ottenere un effetto prolungato nel tempo |
| EP2544660B1 (en) * | 2010-03-10 | 2018-06-13 | Lupin Limited | Rifaximin ready-to-use suspension |
| MX350448B (es) * | 2011-02-11 | 2017-09-07 | Salix Pharmaceuticals Ltd | Formas de rifaximina y usos de las mismas. |
| EP2705042A1 (en) * | 2011-05-02 | 2014-03-12 | Ranbaxy Laboratories Limited | Rifaximin dimethylformamide solvate |
| ITBO20110461A1 (it) | 2011-07-29 | 2013-01-30 | Alfa Wassermann Spa | Composizioni farmaceutiche comprendenti rifaximina, processi per la loro preparazione e loro uso nel trattamento di infezioni vaginali. |
| EP2773205B1 (en) | 2011-11-02 | 2024-05-22 | Salix Pharmaceuticals, Inc. | Rifaximin for retreating diarrhea-predominant irritable bowel syndrome |
| CA2876737A1 (en) | 2012-06-13 | 2013-12-19 | Apotex Pharmachem Inc. | Polymorphic forms of rifaximin |
| ITBO20120368A1 (it) | 2012-07-06 | 2014-01-07 | Alfa Wassermann Spa | Composizioni comprendenti rifaximina e amminoacidi, cristalli di rifaximina derivanti da tali composizioni e loro uso. |
| JP2015528506A (ja) * | 2012-09-13 | 2015-09-28 | サリックス ファーマスーティカルズ，インコーポレーテッド | 体重減少及び肥満の治療のためのリファキシミンの投与の方法 |
| CA2897758A1 (en) | 2013-03-15 | 2014-09-18 | Alfa Wassermann S.P.A. | Rifaximin for use in the treating of vaginal infections |
| EP2971062A2 (en) | 2013-03-15 | 2016-01-20 | ALFA WASSERMANN S.p.A. | Method for diagnosing vaginal infections |
| EA032705B1 (ru) | 2013-04-12 | 2019-07-31 | Альфасигма С.П.А. | Способ лечения или предупреждения энтеропатии |
| ITMI20131307A1 (it) * | 2013-08-02 | 2015-02-02 | A M S A Anonima Materie Sint & Affini S P A | Processo per la preparazione di refaximina k |
| ES2621557T3 (es) | 2014-03-31 | 2017-07-04 | Euticals S.P.A. | Mezcla polimórfica de rifaximina y su uso para la preparación de formulaciones sólidas |
| WO2015171493A1 (en) | 2014-05-04 | 2015-11-12 | Salix Pharmaceuticals, Inc. | Ibs microbiota and uses thereof |
| DK3546464T3 (da) | 2014-05-12 | 2020-07-27 | Alfasigma Spa | Fremstilling og anvendelse af den krystallinske form tau af rifaximin solvateret med degme |
| WO2025170483A1 (ru) * | 2024-02-07 | 2025-08-14 | Общество с ограниченной ответственностью "БИННОФАРМ ГРУПП" | Фармацевтическая композиция, обладающая антибиотической активностью |
Family Cites Families (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7927613B2 (en) * | 2002-02-15 | 2011-04-19 | University Of South Florida | Pharmaceutical co-crystal compositions |
| US7902206B2 (en) * | 2003-11-07 | 2011-03-08 | Alfa Wassermann, S.P.A. | Polymorphic forms α, β and γ of rifaximin |
| ITMI20032144A1 (it) * | 2003-11-07 | 2005-05-08 | Alfa Wassermann Spa | Forme polimorfe di rifaximina, processi per ottenerle e |
| US9682043B2 (en) * | 2003-12-09 | 2017-06-20 | Medcrystalforms, Llc | Method of preparation of mixed phase co-crystals with active agents |
| JP5017103B2 (ja) * | 2004-06-17 | 2012-09-05 | トランスフオーム・フアーマシユーチカルズ・インコーポレーテツド | 薬剤共結晶組成物および関連した使用方法 |
| US7709634B2 (en) * | 2007-09-20 | 2010-05-04 | Apotex Pharmachem Inc. | Amorphous form of rifaximin and processes for its preparation |
| US8486956B2 (en) * | 2008-02-25 | 2013-07-16 | Salix Pharmaceuticals, Ltd | Forms of rifaximin and uses thereof |
| GEP20135898B (en) * | 2008-02-25 | 2013-08-12 | Salix Pharmaceuticals Ltd | Rifaximin forms and usage |
-
2011
- 2011-06-03 MX MX2012013945A patent/MX2012013945A/es not_active Application Discontinuation
- 2011-06-03 EA EA201270808A patent/EA022490B1/ru not_active IP Right Cessation
- 2011-06-03 US US13/152,804 patent/US8513275B2/en active Active
- 2011-06-03 SG SG10201507035UA patent/SG10201507035UA/en unknown
- 2011-06-03 WO PCT/US2011/039085 patent/WO2011153444A1/en not_active Ceased
- 2011-06-03 NZ NZ710780A patent/NZ710780A/en unknown
- 2011-06-03 PH PH1/2012/502393A patent/PH12012502393A1/en unknown
- 2011-06-03 CN CN2011800382176A patent/CN103269587A/zh active Pending
- 2011-06-03 JP JP2013513376A patent/JP2013527246A/ja active Pending
- 2011-06-03 BR BR112012030783A patent/BR112012030783A2/pt not_active Application Discontinuation
- 2011-06-03 SG SG2012082541A patent/SG185490A1/en unknown
- 2011-06-03 CA CA2800668A patent/CA2800668A1/en not_active Abandoned
- 2011-06-03 KR KR1020137000060A patent/KR20130086338A/ko not_active Ceased
- 2011-06-03 NZ NZ603590A patent/NZ603590A/en unknown
- 2011-06-03 AU AU2011261283A patent/AU2011261283B2/en active Active
- 2011-06-03 EP EP11790471.4A patent/EP2575464A4/en not_active Ceased
-
2012
- 2012-11-06 IL IL222900A patent/IL222900A/en active IP Right Grant
- 2012-11-09 TN TNP2012000533A patent/TN2012000533A1/en unknown
- 2012-11-21 ZA ZA2012/08770A patent/ZA201208770B/en unknown
- 2012-12-10 CR CR20120620A patent/CR20120620A/es unknown
-
2013
- 2013-07-31 US US13/955,660 patent/US8815888B2/en active Active
Also Published As
| Publication number | Publication date |
|---|---|
| CN103269587A (zh) | 2013-08-28 |
| PH12012502393A1 (en) | 2013-02-11 |
| SG10201507035UA (en) | 2015-10-29 |
| AU2011261283A1 (en) | 2012-12-06 |
| TN2012000533A1 (en) | 2014-04-01 |
| ZA201208770B (en) | 2013-07-31 |
| BR112012030783A2 (pt) | 2015-09-29 |
| EA022490B1 (ru) | 2016-01-29 |
| US20120108620A1 (en) | 2012-05-03 |
| NZ603590A (en) | 2015-08-28 |
| IL222900A (en) | 2017-11-30 |
| JP2013527246A (ja) | 2013-06-27 |
| KR20130086338A (ko) | 2013-08-01 |
| EP2575464A1 (en) | 2013-04-10 |
| US20130317225A1 (en) | 2013-11-28 |
| WO2011153444A1 (en) | 2011-12-08 |
| AU2011261283B2 (en) | 2015-05-14 |
| IL222900A0 (en) | 2012-12-31 |
| SG185490A1 (en) | 2012-12-28 |
| US8815888B2 (en) | 2014-08-26 |
| CA2800668A1 (en) | 2011-12-08 |
| EP2575464A4 (en) | 2013-10-02 |
| CR20120620A (es) | 2014-05-23 |
| US8513275B2 (en) | 2013-08-20 |
| NZ710780A (en) | 2017-02-24 |
| EA201270808A1 (ru) | 2013-04-30 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MX2012013945A (es) | Nuevas formas de rifaximina y usos de las mismas. | |
| CR20130033A (es) | Formulaciones de rifaximina y usos de las mismas | |
| MX353827B (es) | Formas de rifaximina y usos de la misma. | |
| UY34278A (es) | Derivados novedosos de oxazina y su uso en el tratamiento de enfermedades | |
| ECSP14013224A (es) | Pirimidinas anilladas sustituidas y uso de las mismas | |
| ECSP15017505A (es) | Imidazo[1,2-a]piridincarboxamidas aminosustituidas y su uso | |
| CR20150401A (es) | Formas de rifaximina y sus usos | |
| CU20120161A7 (es) | 5-fluoro-1h-pirazolopiridinas sustituidas | |
| UY34350A (es) | Derivados de pirazolquinolinona, su preparación y su uso terapéutico. | |
| MX2015012414A (es) | Sal de omecamtiv mecarbilo y proceso para preparar la sal. | |
| UY34651A (es) | ?formas de dosificación de liberación inmediata resistentes a la manipulación, procesos para prepararlas, métodos y usos de las mismas?.. | |
| MX2015003140A (es) | Formulaciones de enzalutamida. | |
| BR112016012129A8 (pt) | métodos para produção, expansão e purificação de células epiteliais do pigmento da retina, composição farmacêutica e uso das células | |
| UY32427A (es) | Composicion farmaceutica, forma farmaceutica, procedimiento para su preparacion, metodos de tratamiento y usos de la misma | |
| CL2012003075A1 (es) | Composicion farmaceutica en solucion de pazopanib, estable y para uso oftalmico; metodo para la preparacion de dicha solucion. | |
| CR20160222U (es) | Formas solidas de acido { [ -(3- clorofenil) -3- hidroxipiridin -2-carbonil] amino} acetico, composiciones, y usos de las mismas | |
| DOP2014000255A (es) | Uracilos sustituidos bicíclicamente y uso de los mismos | |
| UY34018A (es) | Derivados glucósidos y usos de los mismos | |
| MX375715B (es) | Profarmacos de metilfenidato, procesos de elaboración y uso de los mismos. | |
| BR112014006482A2 (pt) | uso de derivados de isossorbida para produção de preparações cosméticas | |
| UY34725A (es) | Nuevos derivados de tienopirimidina, procesos para su preparación y sus usos terapéuticos. | |
| UY35693A (es) | Pirazolo[1,5-a]piridin-3-carboxamidas sustituidas y su uso | |
| UY35652A (es) | Bencil-1h-pirazolo[3,4-b]piridinas y su uso | |
| GT201500069A (es) | Piridinonas bicìclicas novedosas | |
| UY34356A (es) | Derivados de estra-1,3,5(10),16-tetraen-3-carboxamida, procedimientos para su preparación, preparados farmacéuticos que los contienen, así como su uso para la preparación de medicamentos |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FA | Abandonment or withdrawal |